

MEETING TITLE			MEETING DATE		
Board Meeting in Public			26/09/2019		
TITLE (DADED	1		D.4.DED.	DEE	
TITLE of PAPER			PAPER	KEF	2.2
KEY PRIORITIES	All				
PURPOSE OF THE PAPER	The purpose of	the paper is to share	the Clinia	cal Stratog	v 2010-202 <i>4</i>
TORTOSE OF THE FALER	with Trust Board			cai Strateg	y 2019-202 <del>4</del>
For Approval		For Assurance			
For Decision	☐ Discussion/Information				
AUTHOR / Dr Steven Dyke LEAD	ACCOUNTABLE DIRECTOR		Dr Julia	ılian Mark	
DISCUSSED AT / INFORMED I	BY – include dat	e(s) as appropriate	[free tex	t - please	provide an
audit trail of the development	(s) / proposal(s)	subject of this pap	er:		
Clinical Strategy Workshops Sept and Oct 2017 – Senior clinical leadership from across the Trust					
Pre Trust Board presentation No		10040			
Critical Friends presentation and			- T	م مالت م مالت م	ماد
Consultation with Medical Direct Quality Committee version 1.2 a		re and Humber Acut	e Trusts a	na Feeaba	ICK
Strategic Leadership Day 07 Ma	• •				
Trust Executive Group 24 April 2019  Board in Private 23 May 2019					
Board III I Mato 20 May 2010					
PREVIOUSLY AGREED AT:	Committe	ee/Group:		Date:	
PREVIOUSLY AGREED AT:	Committe Board of I	• • • • • • • • • • • • • • • • • • •		<b>Date:</b> 23/05/201	9
	Board of [	Directors .	Board app	23/05/201	
PREVIOUSLY AGREED AT:  RECOMMENDATION(S)	Board of [	• • • • • • • • • • • • • • • • • • •	Board app	23/05/201	
RECOMMENDATION(S)	Board of I	Directors .	Board app	23/05/201 rove the C	linical
RECOMMENDATION(S) RISK ASSESSMENT	It is recom Strategy	Directors  Inmended that Trust E		23/05/201 rove the C	linical No
RECOMMENDATION(S)	It is recom Strategy	Directors  Inmended that Trust E		23/05/201 rove the C	linical
RECOMMENDATION(S)  RISK ASSESSMENT  Corporate Risk Register and/o	It is recom Strategy or Board Assura	Directors  Inmended that Trust E		23/05/201 rove the C	linical No
RECOMMENDATION(S)  RISK ASSESSMENT  Corporate Risk Register and/o  If 'Yes' – expand in Section 4. / attache  Equality Impact Assessment  If 'Yes' – expand in Section 2. / attache	It is recom Strategy  or Board Assura ed paper  ed paper	Directors  Inmended that Trust E		23/05/201 rove the C  Yes	linical  No
RECOMMENDATION(S)  RISK ASSESSMENT  Corporate Risk Register and/o If 'Yes' – expand in Section 4. / attached  Equality Impact Assessment	It is recom Strategy  or Board Assura ed paper ed paper cial, Workforce,	Directors  Inmended that Trust E		23/05/201 rove the C  Yes	Iinical  No
RECOMMENDATION(S)  RISK ASSESSMENT  Corporate Risk Register and/of fryes' – expand in Section 4. / attached  Equality Impact Assessment If 'Yes' – expand in Section 2. / attached  Resource Implications (Finance of the fryes' – expand in Section 2. / attached of the frye	It is recomstrategy  or Board Assurated paper  ed paper  cial, Workforce, ed paper  r requirements	Directors  Inmended that Trust E		23/05/201 rove the C  Yes	Iinical  No
RISK ASSESSMENT  Corporate Risk Register and/o  If 'Yes' – expand in Section 4. / attache  Equality Impact Assessment  If 'Yes' – expand in Section 2. / attache  Resource Implications (Finance If 'Yes' – expand in Section 2. / attache  Legal implications/Regulatory  If 'Yes' – expand in Section 2. / attache	It is recomstrategy  or Board Assurated paper  ed paper  cial, Workforce, ed paper  r requirements	Directors  Inmended that Trust E		23/05/201 rove the C  Yes	Iinical  No
RECOMMENDATION(S)  RISK ASSESSMENT  Corporate Risk Register and/o  If 'Yes' – expand in Section 4. / attache  Equality Impact Assessment  If 'Yes' – expand in Section 2. / attache  Resource Implications (Finance  If 'Yes' – expand in Section 2. / attache  Legal implications/Regulatory  If 'Yes' – expand in Section 2. / attache  ASSURANCE/COMPLIANCE	It is recomstrategy  or Board Assurated paper  ed paper  cial, Workforce, ed paper  r requirements	other - specify)		23/05/201 rove the C  Yes	Iinical  No
RECOMMENDATION(S)  RISK ASSESSMENT  Corporate Risk Register and/of fryes' – expand in Section 4. / attached and fryes' – expand in Section 2. / attached fryes'	It is recomstrategy  or Board Assurated paper  ed paper  cial, Workforce, ed paper  r requirements	Directors  Inmended that Trust E		23/05/201 rove the C  Yes	Iinical  No
RECOMMENDATION(S)  RISK ASSESSMENT  Corporate Risk Register and/o  If 'Yes' – expand in Section 4. / attache  Equality Impact Assessment  If 'Yes' – expand in Section 2. / attache  Resource Implications (Finance  If 'Yes' – expand in Section 2. / attache  Legal implications/Regulatory  If 'Yes' – expand in Section 2. / attache  ASSURANCE/COMPLIANCE	It is recomstrategy  or Board Assurated paper  ed paper  cial, Workforce, ed paper  r requirements	other - specify)		23/05/201 rove the C  Yes	Iinical  No

### Clinical Strategy 2019-2024

#### 1. PURPOSE/AIM

1.1 The purpose of the paper is to share the Clinical Strategy 2019-2024 with Trust Board for approval.

### 2. BACKGROUND/CONTEXT

- 2.1 The Clinical Strategy will support the delivery of an integrated urgent and emergency care service which will save lives and ensure everyone in our communities receives the right care, whenever and wherever they need it, and will put the patient and clinician at the heart of the organisation through three core aims:
  - Continuous improvement and innovation of clinical care,
  - Enabling our multidisciplinary team to deliver high quality, person-centred, Evidence-based care and,
  - Ensuring that patients experience a consistently safe, compassionate, high standard of care.
- 2.2 The Clinical Stagey has been developed over the last year with input from senior clinicians and managers across all service lines in the Yorkshire Ambulance Service, and externally, with input and feedback from Medical Directors and Senior Clinicians from external stakeholders, including Secondary Care.

#### 3. PROPOSALS/NEXT STEPS

3.1 Following presentation to Trust Board, the Clinical Strategy will be launched, with retrospective approval by Trust Board at its next meeting in public.

#### 4. RISK ASSESSMENT

- 4.1 The Clinical Strategy links to the following risks described on the Board Assurance Framework
  - 1a Inability to deliver National performance targets and clinical quality standards
  - 3a System-wide lack of availability of workforce and impact of changes to funding streams on provision of education and training.
  - 3c Ineffective strategies for leadership and engagement and a developed organisational culture.
  - 4a Impact of external system pressures and changes in wider health economy
  - 5a inefficient joint working between corporate and operational services

# 5. **RECOMMENDATIONS**

It is recommended that Trust Board approve the Clinical Strategy.

# 6. APPENDIX

Clinical Strategy 2019-2024